Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Adjuvant Therapy in Resected ESCC with pCR
NCT06903871Phase 2Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Apr 2025
- Primary completion
- Mar 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: 1-year Disease free survival rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06903871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903871.